Poster 54

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Evaluation of Lipid Parameters in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Authors: Mark Lebwohl, Bruce Strober, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta

< PREVIOUS POSTER NEXT POSTER >

POSTER 54